Back to Results
First PageMeta Content
J. Michael Pearson / Rifaximin / Allergan / Chemistry / Pharmacology / Medicine / Companies listed on the New York Stock Exchange / Valeant Pharmaceuticals / Willow


Valeant ups Salix bid to $11.11B and Endo ends quest (Update)
Add to Reading List

Document Date: 2015-05-28 13:02:04

Open Document

File Size: 30,54 KB

Share Result on Facebook

City

Montreal / Raleigh / /

Company

The Associated Press / Bausch / Endo International PLC / Valeant Pharmaceutical / Valeant Pharmaceuticals International Inc. / Allergan / Pharmacyclics / Salix Pharmaceuticals Ltd. / AP Photo/The Canadian Press / /

Country

Canada / Ireland / /

Currency

USD / /

Event

Natural Disaster / Earnings Announcement / M&A / /

Facility

Valeant Pharmaceutical's headquarters / /

IndustryTerm

cancer treatment / /

MedicalCondition

rheumatoid arthritis / Crohn's disease / gastroesophageal reflux / opioid-induced constipation / liver cirrhosis / blood cancer / constipation / irritable bowel syndrome / /

Person

J. Michael Pearson / Ryan Remiorz / /

Position

leader / Chairman and CEO / /

Product

Zegerid / Pepcid / /

ProvinceOrState

North Carolina / /

Technology

drug development / /

URL

www.tcpdf.org / http /

SocialTag